Project description:Schisandra chinensis fruit extract (SCE) and its active ingredient Schisandrin B (SchB), which are effective in the treatment of vascular diseases, have been known to suppress transforming growth factor β1 (TGF-β1)-mediated Smad activation and myosin light chain (MLC) phosphorylation in vascular smooth muscle cells (VSMCs). However, it is still largely unknown about the pharmacologic effects and mechanisms of SCE and SchB on TGF-β1-induced intracellular signaling pathways in vascular smooth muscle cells (VSMCs).
Project description:We reported the application of high-throughput sequencing technology (RNA-seq) for the transcriptome of T. chinensis cells and the transcriptional alternatives of that responded to MeJA were comprehensively and quantitatively assessed with high-throughput sequencing technology (RNA-seq). By sequencing > 29 million reads (200 bp in length) of cDNA from each of MeJA-treated T. chinensis cells at 16 h (T16) and the control (T0), we identified 46,581 transcripts and uncovered 13,469 genes differentially expressed in response to MeJA. We provided functional clues for understanding the regulation mechanisms of MeJA-mediated defense responses and taxol biosynthesis.